CRL - CHRLS RIVER LABS （）

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River Laboratories (CRL) has sold its Avian Vaccine Services business to private equity firm Arlington Capital Partners.The business, now AVS Bio, will operate independently as…

In September 2021, Syneos Health entered into a strategic collaboration with Ride Health to offer non-emergency medical transportation (NEMT) for clinical trial participants. Northbrook, IL 60062 -- ( SBWIRE ) -- 12/15/2022 -- The Global Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) - Global Forecast to 2026" published by MarketsandMarkets, the clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period. Factors such as growing R&D expenditure, increasing outsourcing of R&D activities, and the rising number of clinical trials worldwide are driving the growth of the global clinical trials market. The growing biosimilars and biologics market, rising demand for specialized testing services, and emerging Asian markets also offer significant growth opportunities for players operating in the market.

Charles River Laboratories (CRL) added ~7% Thursday after Cambodia dismissed reports of restrictions on its exports of monkeys for medical research. Read the full story here.

Major players in the stem cell assay market are Thermo Fisher Scientific Inc. , Merck Group, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, PerkinElmer, Agilent Technologies, Promega Biotechnology Company, Cell Biolabs, Miltenyi Biotec, STEMCELL Technologies, Bio-Techne Corporation, Charles River Laboratories International Inc. Major players in the stem cell assay market are Thermo Fisher Scientific Inc. , Merck Group, Danaher Corporation, Becton Dickinson and Company, Bio-Rad Laboratories, PerkinElmer, Agilent Technologies, Promega Biotechnology Company, Cell Biolabs, Miltenyi Biotec, STEMCELL Technologies, Bio-Techne Corporation, Charles River Laboratories International Inc.

At the close of the New York Stock Exchange, the Dow Jones rose 2.18% to a 6-month high, the S&P 500 rose 3.09% and the NASDAQ Composite index rose 4.41%. The leading gainers among the components of the Dow Jones index today were shares of Microsoft Corporation, which gained 14.81 points (6.16%) to close at 255.14. Salesforce Inc rose 8.57 points or 5.65% to close at 160.25. Apple Inc rose 4.86% or 6.86 points to close at 148.03. The least gainers were Walmart Inc, which shed 0.55 points or 0.36% to end the session at 152.42. 3M Company rose 0.13% or 0.16 points to close at 125.97, while Caterpillar Inc rose 0.55% or 1.29 points to close at 236.41 . Leading gainers among the S&P 500 index components in today''s trading were Estee Lauder Companies Inc (NYSE:EL), which rose 9.70% to 235.79, Netflix Inc, which gained 8.75% to close at 305.53, as well as shares of Hewlett Packard Enterprise Co, which rose 8.57% to close the session at 16.79. The least gainers were NetApp Inc, which shed 5.82% to close at 67.61.

Shares of Charles River Laboratories International Inc. fell in morning trading Wednesday after the non-clinical contract research company warned that supplies of Cambodia-sourced monkeys will likely be challenging for some period of time. The post Challenges to Cambodia monkey supply causes Charles River Laboratories International in US to fall appeared first on Khmer Times .

Charles River Laboratories and Labcorp shares fall on potential NHP supply issues

Charles River Laboratories (CRL) was among notable decliners in the S&P 500 on Wednesday after the non-clinical contract research organization announced that a recent DoJ indictment…

After Charles River’s quick and strong recovery in recent weeks, should investors take profits or hold? Read more to see a full analysis of CRL stock.

Upgrades According to TD Securities, the prior rating for Brookfield Renewable Partners LP (NYSE: BEP ) was changed from Buy to Action List Buy. Brookfield Renewable earned $0.03 in the second quarter, compared to $0.13 in the year-ago quarter. The current stock performance of Brookfield Renewable shows a 52-week-high of $41.95 and a 52-week-low of $30.85. Moreover, at the end of the last trading period, the closing price was at $30.94. Citigroup upgraded the previous rating for Agnico Eagle Mines Ltd (NYSE: AEM ) from Neutral to Buy. In the second quarter, Agnico Eagle Mines showed an EPS of $0.75, compared to $0.69 from the year-ago quarter. At the moment, the stock has a 52-week-high of $67.14 and a 52-week-low of $36.69. Agnico Eagle Mines closed at $41.43 at the end of the last trading period. For Bed Bath & Beyond Inc (NASDAQ: BBBY ), Odeon Capital upgraded the previous rating of Sell to Hold. In the second quarter, Bed Bath & Beyond showed an EPS of $3.22, compared to $0.04 from the year-ago quarter.

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW ) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. When asked about Charles River Laboratories International, Inc. (NYSE: CRL ), Cramer said, "It finally doesn’t have a high price-to-earnings multiple. I would actually start … Full story available on Benzinga.com

Charles River Laboratories (CRL) gained in the pre-market trading Friday after Jefferies upgraded the non-clinical contract research organization ((CRO)) to Buy from Hold, noting…

"Mad Money" host Jim Cramer rings the lightning round bell, which means he''s giving his answers to callers'' stock questions at rapid speed.